Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan vs esomeprazole bismuth-based quadruple therapy for Helicobacter pylori eradication
ChiCTR2500108329Phase 4Not yet recruiting
- Sponsor
- Air Force Hospital of the Northern Theater Command of the PLA
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of keverprazan in Helicobacter pylori infection (2 arms), sponsored by Air Force Hospital of the Northern Theater Command of the PLA. Primary endpoints: Helicobacter pylori eradication rate and Clinical symptom improvement status. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500108329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108329.